PG
NVIV

PEAK6 Group’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

PEAK6 Group’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed -$82K – 5654
2015
Q3 		$82K Buy
+1
New +$234K ﹤0.01% 4432

Other funds holding NVIV

WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PEAK6 Group's NVIV Position: Q4 2015 in Review

PEAK6 Group sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q4 2015, closing a stake of 1 share — an estimated $82K sold.

PEAK6 Group first reported a position in NVIV in Q3 2015 and held it in 1 quarter. The position peaked at $82K in Q3 2015. 38 funds tracked by Wall St. Rank hold NVIV as of Q4 2015.

  • PEAK6 Group reported no remaining InVivo Therapeutics Holdings Corp position as of Q4 2015 after selling out during the quarter.
  • PEAK6 Group sold 1 InVivo Therapeutics Holdings Corp share in Q4 2015, an estimated $82K.
  • PEAK6 Group first reported a position in InVivo Therapeutics Holdings Corp in Q3 2015 and held it in 1 quarter.
  • PEAK6 Group's InVivo Therapeutics Holdings Corp position peaked at $82K in Q3 2015.
  • 38 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q4 2015.

Based on PEAK6 Group's 13F filing for Q4 2015, filed 16 Feb 2016.